Proactive Investors - Run By Investors For Investors

Cronos Group reports higher revenue but widening loss in mixed 4Q earnings results

In March, the Canadian cannabis producer closed a $2.4 billion investment from Marlboro cigarette maker Altria Inc
cannabis plant
The Toronto-based company attributed revenue growth for the quarter to shipments to the Canadian adult-use market and a growth in cannabis oil proceeds

Cronos Group Inc (NASDAQ:CRON) (TSE:CRON) saw revenue rise in the fourth quarter of 2018 but still reported a net loss for the period as it released its quarterly and year-end earnings early Tuesday.

Shares of Cronos slipped more than 3% in morning trading as the Canadian cannabis producer reported 4Q revenue of US$5.6 million, significantly higher than the $1.6 million for the same period last year.

However, the company still had a net loss of $11.6 million during the quarter, or $0.06 per share. The cannabis producer swung from a profit of a penny per share in the year-ago quarter.

The Toronto-based company attributed revenue growth for the quarter to shipments to the Canadian adult-use market and a growth in cannabis oil proceeds.

READ: Altria makes C$2.4B investment in Canadian cannabis company Cronos Group

Analysts were expecting to see a loss of $0.01 on earnings of $7.8 million for the quarter. Cronos missed on both metrics.

Full-year revenue for 2018 was C$19.2 million, compared with C$1.8 million in 2017 but, again, a net loss of C$0.11 per share versus a penny profit a year ago. 

“Over the past year, Cronos Group has diligently focused on our strategic objectives, which culminated in our transformative partnership with Altria Group, Inc.,” said Mike Gorenstein, CEO of Cronos Group. “We’ve expanded our production footprint domestically and internationally, developed our distribution with global partnerships, launched iconic brands for the Canadian adult-use market and grown our IP portfolio with landmark research and development initiatives.”

In March 2019, Cronos closed a $2.4 billion equity investment from Marlboro cigarette maker Altria Inc. Altria now holds 45% of Cronos shares, with an option to increase its stake to 55% under the agreement.

Shares of Cronos were trading at US$19.80 in New York and slipped 1% to C$27.10 in Toronto on Tuesday morning.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas


View full CRON profile View Profile

Cronos Group Inc Timeline

Related Articles

Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use